BioCentury | Mar 9, 2015
Company News

BioArctic, Biotecnol deal

...The companies will use Biotecnol’s Tribody technology and BioArctic’s anti-amyloid beta antibodies to develop an in...
...for Alzheimer’s disease (AD). The research will be conducted at Uppsala University . According to Biotecnol...
...The companies did not respond to requests for details. BioArctic Neuroscience AB , Stockholm, Sweden Biotecnol Ltd....
BioCentury | Feb 4, 2013
Company News

Biotecnol Inc., Chiome deal

...cytokines or protein toxins can be incorporated. The companies could not be reached for details. Biotecnol...
BioCentury | Oct 29, 2012
Company News

Biotecnol Inc., PolyTherics deal

...treat cancer. The companies will use PolyTherics' ThioBridge conjugation technology to attach cytotoxic drugs on Biotecnol's...
...or protein toxins can be incorporated. The partners will share IP rights to the candidates. Biotecnol...
...develop the most advanced candidate through clinical testing. The companies declined to disclose financial details. Biotecnol...
BioCentury | Sep 26, 2011
Clinical News

Cardiotrophin-1 regulatory update

...Phase II trial in acute liver failure by year end 2012. In 2009, Digna and Biotecnol...
...for use in certain liver indications. Genentech has an exclusive option to IP co-developed under Biotecnol...
...the U.S. and EU for the prevention of ischemic/reperfusion injury associated with solid organ transplantation. Biotecnol...
BioCentury | Aug 25, 2011
Cover Story

Cardiotrophin workout

...they acknowledged that longer term cardiovascular toxicology studies are needed. In 2009, Digna and partner Biotecnol...
...Osherovich, L. SciBX 4 (33); doi:10.1038/scibx.2011.922 Published online Aug. 25, 2011 Companies and Institutions Mentioned Biotecnol...
BioCentury | Mar 21, 2011
Clinical News

Cardiotrophin-1: Phase I start

...Next quarter, Digna and Biotecnol will start a dose-escalation, Spanish Phase I trial to evaluate 0.3-180...
...CT-1 under an amended 2007 deal (see BioCentury, Aug. 4, 2008). In 2009, Digna and Biotecnol...
...for use in certain liver indications. Genentech has an exclusive option to IP co-developed under Biotecnol...
BioCentury | Sep 14, 2009
Company News

Biotecnol S.A., Digna Biotech, Roche deal

...under Biotecnol and Digna's 2007 CT-1 collaboration for liver indications. If Genentech exercises its option, Biotecnol...
...in the U.S. and Europe for use in liver transplantation (see BioCentury, Aug. 4, 2008). Biotecnol...
BioCentury | May 25, 2009
Clinical News

Biotecnol, Digna Biotech preclinical data

...in the U.S. and Europe for use in liver transplantation (see BioCentury, Aug. 4, 2008). Biotecnol...
BioCentury | Feb 16, 2009
Company News

Biotecnol management update

Biotecnol S.A. , Oeiras, Portugal Business: Cancer, Antibodies Appointed: Nico Mertens as director of antibody engineering programs WIR Staff cancer...
BioCentury | Feb 9, 2009
Company News

Biotecnol S.A., INSERM, Hopitaux Universitaires de Strasbourg, Universite Louis Pasteur deal

...The institutions granted Biotecnol an exclusive, worldwide license to develop and commercialize IP covering parathyroid hormone-related...
...and commercialize IP covering parathyroid hormone-related protein (PTHrP) antagonists to treat renal cell carcinoma (RCC). Biotecnol...
...compound this year and begin clinical testing in 2H10 . Financial terms are not disclosed. Biotecnol...
Items per page:
1 - 10 of 15
BioCentury | Mar 9, 2015
Company News

BioArctic, Biotecnol deal

...The companies will use Biotecnol’s Tribody technology and BioArctic’s anti-amyloid beta antibodies to develop an in...
...for Alzheimer’s disease (AD). The research will be conducted at Uppsala University . According to Biotecnol...
...The companies did not respond to requests for details. BioArctic Neuroscience AB , Stockholm, Sweden Biotecnol Ltd....
BioCentury | Feb 4, 2013
Company News

Biotecnol Inc., Chiome deal

...cytokines or protein toxins can be incorporated. The companies could not be reached for details. Biotecnol...
BioCentury | Oct 29, 2012
Company News

Biotecnol Inc., PolyTherics deal

...treat cancer. The companies will use PolyTherics' ThioBridge conjugation technology to attach cytotoxic drugs on Biotecnol's...
...or protein toxins can be incorporated. The partners will share IP rights to the candidates. Biotecnol...
...develop the most advanced candidate through clinical testing. The companies declined to disclose financial details. Biotecnol...
BioCentury | Sep 26, 2011
Clinical News

Cardiotrophin-1 regulatory update

...Phase II trial in acute liver failure by year end 2012. In 2009, Digna and Biotecnol...
...for use in certain liver indications. Genentech has an exclusive option to IP co-developed under Biotecnol...
...the U.S. and EU for the prevention of ischemic/reperfusion injury associated with solid organ transplantation. Biotecnol...
BioCentury | Aug 25, 2011
Cover Story

Cardiotrophin workout

...they acknowledged that longer term cardiovascular toxicology studies are needed. In 2009, Digna and partner Biotecnol...
...Osherovich, L. SciBX 4 (33); doi:10.1038/scibx.2011.922 Published online Aug. 25, 2011 Companies and Institutions Mentioned Biotecnol...
BioCentury | Mar 21, 2011
Clinical News

Cardiotrophin-1: Phase I start

...Next quarter, Digna and Biotecnol will start a dose-escalation, Spanish Phase I trial to evaluate 0.3-180...
...CT-1 under an amended 2007 deal (see BioCentury, Aug. 4, 2008). In 2009, Digna and Biotecnol...
...for use in certain liver indications. Genentech has an exclusive option to IP co-developed under Biotecnol...
BioCentury | Sep 14, 2009
Company News

Biotecnol S.A., Digna Biotech, Roche deal

...under Biotecnol and Digna's 2007 CT-1 collaboration for liver indications. If Genentech exercises its option, Biotecnol...
...in the U.S. and Europe for use in liver transplantation (see BioCentury, Aug. 4, 2008). Biotecnol...
BioCentury | May 25, 2009
Clinical News

Biotecnol, Digna Biotech preclinical data

...in the U.S. and Europe for use in liver transplantation (see BioCentury, Aug. 4, 2008). Biotecnol...
BioCentury | Feb 16, 2009
Company News

Biotecnol management update

Biotecnol S.A. , Oeiras, Portugal Business: Cancer, Antibodies Appointed: Nico Mertens as director of antibody engineering programs WIR Staff cancer...
BioCentury | Feb 9, 2009
Company News

Biotecnol S.A., INSERM, Hopitaux Universitaires de Strasbourg, Universite Louis Pasteur deal

...The institutions granted Biotecnol an exclusive, worldwide license to develop and commercialize IP covering parathyroid hormone-related...
...and commercialize IP covering parathyroid hormone-related protein (PTHrP) antagonists to treat renal cell carcinoma (RCC). Biotecnol...
...compound this year and begin clinical testing in 2H10 . Financial terms are not disclosed. Biotecnol...
Items per page:
1 - 10 of 15